Diepgen TL, Ofenloch RF, Bruze M, et al. Prevalence of contact allergy in the general population in different European regions. Br J Dermatol. 2016;174(2):319–29.

CAS  PubMed  Google Scholar 

Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy. 2007;37(4):526–35.

CAS  PubMed  Google Scholar 

Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595–605.

PubMed  Google Scholar 

Saeki H, Tsunemi Y, Fujita H, et al. Prevalence of atopic dermatitis determined by clinical examination in Japanese adults. J Dermatol. 2006;33(11):817–9.

PubMed  Google Scholar 

Belmesk L, Muntyanu A, Cantin E, et al. Prominent role of type 2 immunity in skin diseases: beyond atopic dermatitis. J Cutan Med Surg. 2022;26(1):33–49.

CAS  PubMed  Google Scholar 

Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62.

CAS  PubMed  Google Scholar 

Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2022;150(3):690–700.

CAS  PubMed  Google Scholar 

Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy Asthma Immunol. 2018;120(1):34–41.

CAS  PubMed  Google Scholar 

Brunner PM, Suárez-Fariñas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8707.

PubMed  PubMed Central  Google Scholar 

Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–76.

CAS  PubMed  PubMed Central  Google Scholar 

Guttman-Yassky E, Facheris P, Gomez-Arias PJ, et al. Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis. Allergy. 2024;79(5):1258–70.

CAS  PubMed  Google Scholar 

Guttman-Yassky E, Kabashima K, Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(6):1560–72.

CAS  PubMed  Google Scholar 

Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915–31.

CAS  PubMed  PubMed Central  Google Scholar 

Mikhaylov D, Del Duca E, Olesen CM, et al. Transcriptomic profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab. Dermatitis. 2021;32(1s):S71–80.

CAS  PubMed  Google Scholar 

Pavel AB, Song T, Kim HJ, et al. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(4):1011–24.

CAS  PubMed  Google Scholar 

Bakker D, de Bruin-Weller M, Drylewicz J, van Wijk F, Thijs J. Biomarkers in atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1163–8.

PubMed  Google Scholar 

Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448–74.

CAS  PubMed  PubMed Central  Google Scholar 

Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-90.e1.

CAS  PubMed  PubMed Central  Google Scholar 

Okragly AJ, Ryuzoji A, Wulur I, et al. Binding, neutralization and internalization of the interleukin-13 antibody. Lebrikizumab Dermatol Ther (Heidelb). 2023;13(7):1535–47.

PubMed  Google Scholar 

Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–91.

CAS  PubMed  Google Scholar 

Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740–8.

CAS  PubMed  Google Scholar 

Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47.

PubMed  PubMed Central  Google Scholar 

Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. bioRxiv 2021:060012.

Konrad RJ, Higgs RE, Rodgers GH, et al. Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay. Sci Rep. 2019;9(1):5211.

PubMed  PubMed Central  Google Scholar 

Leung DYM, Calatroni A, Zaramela LS, et al. The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype. Sci Transl Med. 2019;11(480):eaav2685.

CAS  PubMed  PubMed Central  Google Scholar 

Tseng PY, Hoon MA. GPR15L is an epithelial inflammation-derived pruritogen. Sci Adv. 2022;8(24):eabm7342.

CAS  PubMed  PubMed Central  Google Scholar 

Farutin V, Kurtagic E, Pradines JR, et al. Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis? Arthritis Res Ther. 2021;23(1):259.

CAS  PubMed  PubMed Central  Google Scholar 

He H, Bissonnette R, Wu J, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147(1):199–212.

CAS  PubMed  Google Scholar 

Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459–64.

CAS  PubMed  Google Scholar 

Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480–9.

CAS  PubMed  PubMed Central  Google Scholar 

Elbe-Bürger A, Egyed A, Olt S, et al. Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol. 2002;118(5):767–78.

PubMed  Google Scholar 

Finkelman FD, Katona IM, Urban JF Jr, et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol. 1988;141(7):2335–41.

CAS  PubMed  Google Scholar 

Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–72.

CAS  PubMed  Google Scholar 

Rojahn TB, Vorstandlechner V, Krausgruber T, et al. Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type-specific immune regulation in atopic dermatitis. J Allergy Clin Immunol. 2020;146(5):1056–69.

CAS  PubMed  Google Scholar 

Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–300.

CAS  PubMed  Google Scholar 

Czarnowicki T, He H, Canter T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2020;145(1):215–28.

CAS  PubMed  Google Scholar 

Uchida AM, Ro G, Qiang L, et al. Human differentiated eosinophils release IL-13 in response to IL-33 stimulation. Front Immunol. 2022;13: 946643.

CAS  PubMed  PubMed Central  Google Scholar 

Le Floc’H A, Allinne J, Nagashima K, et al. Il-4 and IL-13 act independently and synergistically to drive type 2 inflammation. Eur Respiratory J. 2019;54(suppl 63):5206.

Google Scholar 

Sonnenberg-Riethmacher E, Miehe M, Riethmacher D. Periostin in allergy and inflammation. Front Immunol. 2021;12: 722170.

CAS